The COVID-19 pandemic caused by SARS-CoV-2 coronavirus continues to affect our community and economy and poses a significant risk to our health. Epidemiologists and viral researchers face an unprecedented demand for faster PCR-based workflow to develop guidance for preventing the further spread of COVID-19 variants. To meet this demand, laboratories need an approach that overcomes the shortage of reagents, cuts the turnaround time and increases the frequency of analysis without compromising performance. It should also seamlessly integrate existing automation with standard lab equipment at all throughput needs.

In this webinar with Dr. Norbert Hochstein, you will discover:

• How a liquid prep-based QIAprep&amp procedure works

• The benefits of using the method

• How it performs compared to other solutions

About the speaker
Dr. Norbert Hochstein, Director, Research & Development
Dr. Norbert Hochstein is Director in the Research & Development department at QIAGEN, Hilden,Germany. He studied biology at the University of Cologne and Erlangen Medical School in Germany, where he received his Ph.D. in 2007. His research focused on Epigenetics and Molecular Virology. After a postdoctoral position at the Department of Genetics and Pathology, Uppsala University, Sweden, Dr. Hochstein started to work for QIAGEN at the end of 2008. In his position in the Research & Development department, he was involved in the merger and acquisition of the Pyrosequencing technology into QIAGEN‘s product portfolio and further expansion. Since 2015, Dr. Hochstein has been heading the product development for single-cell applications and later in 2018 also for PCR and real-time PCR.
Date of recording:Tuesday, March 2, 2021
Duration:1 hour
Molecular Biology
Liquid Biopsy
Infectious Disease